Similarly, a SL CRISPR/Cas9 screen in an RB1−/− SCLC cell line with inducible expression of RB1 showed that Aurora B kinase or its kinase inhibitor, AZD2811, were efficacious in multiple preclinical SCLC models [17]. This evidence concerns the gene AURKB and small cell lung carcinoma.